Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

regimens of the Phase 2b study of un-boosted RG7227 plus SOC are expected to be reported late in the first quarter or early in the second quarter of 2010.  
  • A Phase 2b study of ritonavir-boosted RG7227 plus SOC is expected to begin in Q3 of 2010.  This study replaces the previously planned 24-week un-boosted regimens of the on-going Phase 2b triple combination study.
  • InterMune and Roche today reported that the next step in the INFORM direct antiviral agent (DAA) program is planned to be a study combining RG7128 with ritonavir-boosted RG7227 involving treatment durations of at least 12 weeks and evaluating sustained virologic response (SVR).  The ritonavir-boosted DAA study to evaluate SVR may begin in the second half of 2010; the exact timing will be based on emerging data from the on-going studies.  The companies also announced today that given the importance of generating longer-term safety and SVR data for ritonavir-boosted RG7227 in combination with RG7128, the previously planned INFORM-2 four-week study will not be conducted.  

  • Financial:

    • On January 29, 2010, InterMune completed a public offering of 8,050,000 shares of common stock, including the underwriters' over-allotment, with net proceeds to the company of $106.8 million (after payment of the underwriting discounts and commissions, and expenses).

    Fourth Quarter and Full-Year 2009 Financial Results (Unaudited)

    InterMune reported total revenue in the fourth quarter of 2009 of $6.6 million, compared with $7.4 million in the fourth quarter of 2008, reflecting lower off-label physician prescriptions of Actimmune® (gamma interferon-1b) for the treatment of IPF, which InterMune does not promote.  Total revenue for the fu
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
    2. InterMune Announces Start of Phase 1b Trial of ITMN-191
    3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
    4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
    5. InterMune Announces Progress on Pirfenidone in IPF
    6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
    7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
    8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
    9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
    10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
    11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
    (Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
    (Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
    Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
    ... , BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ... that the US Patent and Trademark Office has allowed its ... stages of the manufacture of the Company,s DCVax® therapeutic cancer ... very high concentration of dendritic cells (which are the critical ...
    ... , RARITAN, N.J., Dec. 4 Depression, anxiety ... disorder and migraine: These are among the comorbidities reported ... had been diagnosed with epilepsy versus those without an ... households across the U.S. , Findings from " CNS-Related ...
    Cached Medicine Technology:Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3
    (Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
    (Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
    (Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
    (Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
    (Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
    Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
    ... Harrisburg, PA-based national dental insurer United Concordia Companies, Inc. has renamed ... Claim, to better communicate the Web-based nature of the service.The online ... , Free electronic claims ... Real-time explanations of benefits (EOBs) , ...
    ... AGA Medical Corporation (AGA) today,announced that, following ... the German court of appeals over Occlutech GmbH,of ... Occlutech of the,amount of damages that it will ... learning that Occlutech has terminated all manufacturing and,sales ...
    ... Jan. 29 A national coalition of ... other,stakeholders, has been created to help breast ... prostheses and related post-surgical items. Known ... for the Advancement, Reform,and Equity), the coalition, ...
    ... Medical Spa Industry Expert and CEO of Acara Medspa Consulting Group, ... 20 MedSpa Professionals from across the nation joined him for this ... ... -- 20 Top MedSpa owners, operators and managers this week attended ...
    ... Columbia Doctors, the Physicians and Surgeons of Columbia University select ... to medical practices and healthcare clinics, as their transcription vendor ... record. , ... Scottsdale, AZ (PRWEB) ...
    ... - A New Year of Growth in 2008, ... - Higher Earnings Expected , ... revenue of EUR3,074.5 million for the year ended,December 31, 2008, representing ... growth for the year was a strong 9.7%. , ...
    Cached Medicine News:Health News:Speed eClaim Helps National Dental Insurer United Concordia Process Claims Quickly, Efficiently and Electronically 2Health News:AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages 2Health News:New Coalition Created to Help Breast Cancer Survivors Gain Access to Products Designed to Improve Their Quality of Life 2Health News:20 MedSpa Professionals Gain Insight into MedSpa Business Turnaround Tactics 2Health News:Columbia Doctors, the Physicians and Surgeons of Columbia University Select MxSecure, Inc., as Their Medical Transcription Vendor of Choice 2Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6
    Disposable Microscissors: Horizontal Curved Microscissors...
    Sharp tipped illuminated scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and...
    Disposable Microscissors: Vertical, 90...
    Sharp tipped scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and all purpose...
    Medicine Products: